BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16093872)

  • 1. Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival.
    Aldulaimi DM; Cox M; Nwokolo CU; Loft DE
    Eur J Gastroenterol Hepatol; 2005 Sep; 17(9):943-50. PubMed ID: 16093872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oesophagectomy is a safe option for early adenocarcinoma arising from Barrett's oesophagus.
    Lam YH; Bright T; Leong M; Thompson SK; Mayne G; Watson DI
    ANZ J Surg; 2016 Nov; 86(11):905-909. PubMed ID: 25708344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland.
    Murphy SJ; Dickey W; Hughes D; O'Connor FA
    Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1029-35. PubMed ID: 16148547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma.
    Hillman LC; Chiragakis L; Clarke AC; Kaushik SP; Kaye GL
    J Gastroenterol Hepatol; 2003 May; 18(5):526-33. PubMed ID: 12702044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
    Incarbone R; Bonavina L; Bassi F; Peracchia A
    Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett's oesophagus.
    Sujendran V; Sica G; Warren B; Maynard N
    Eur J Cardiothorac Surg; 2005 Nov; 28(5):763-6. PubMed ID: 16188449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surveillance for Barrett's oesophagus: worthwhile?].
    Kastelein F; Kuipers EJ
    Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus.
    Fitzgerald RC; Saeed IT; Khoo D; Farthing MJ; Burnham WR
    Dig Dis Sci; 2001 Sep; 46(9):1892-8. PubMed ID: 11575441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer.
    Streitz JM; Ellis FH; Tilden RL; Erickson RV
    Am J Gastroenterol; 1998 Jun; 93(6):911-5. PubMed ID: 9647017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
    Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
    Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barrett's oesophagus: a review of costs of the illness.
    Arguedas MR; Eloubeidi MA
    Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Audit of a Barrett's epithelium surveillance database.
    Basu KK; Pick B; de Caestecker JS
    Eur J Gastroenterol Hepatol; 2004 Feb; 16(2):171-5. PubMed ID: 15075990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?
    Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T
    Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.